Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts 776
Year : 2014  |  Volume : 5  |  Issue : 2  |  Page : 159-165

Preclinical pharmacological profile of Eberconazole: A review and update

1 Dr. Reddy's Laboratories Ltd., Hyderabad, Andhra Pradesh, India
2 Director of Research and Study Director, Indian Institute of Toxicology, Pune, Maharashtra, India
3 Department of Veterinary Pharmacology and Toxicology, College of Veterinary Science, Hyderabad, Andhra Pradesh, India
4 Department of Pharmacology, Azeezia Medical College, Kollam, Kerala, India

Correspondence Address:
Latha Subramanya Moodahadu
G5, Mount Meru Apt, Road 5, Avenue 7, Banjara Hills, Hyderabad - 500 034, Andhra Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: Dr M S Latha, Dr Ashis Patnaik, Dr VV Arvind and Dr Shantala B, are the employees of Dr Reddy’s Laboratories Ltd., which is marketing Eberconazole in India. These authors are stakeholders having fi nancial stakes in Dr. Reddy’s Laboratories Ltd. by means of salary, company stocks or both. Dr Binny Krishnankutty & Dr Katta Kavitha are former employees of Dr Reddy’s Laboratories Ltd and presently not having any stakes in Dr. Reddy’s Laboratories Ltd. Dr RM Bhide is not having any confl ict of interest.

DOI: 10.4103/0975-9727.135757

Rights and Permissions

Eberconazole is a broad-spectrum imidazole antifungal agent used as a topical preparation in the management of cutaneous mycoses. In vitro studies have shown that eberconazole is effective against dermatophytes, candidiasis, yeasts (including those which are triazole resistant) and Pityriasis versicolor. It inhibits fungal lanosterol 14α-demethylase, thereby inhibiting ergosterol synthesis leading to inhibition of fungal growth. In addition to its antifungal activity, it is also effective against Gram-positive bacteria, a property that is useful clinically. It also possesses anti-inflammatory property thus making it a suitable agent in the clinical management of inflamed cutaneous mycoses. Topical application of eberconazole was well tolerated in preclinical studies without any report of delayed hypersensitivity or photosensitivity reactions. There were no phototoxic effects. There was no significant systemic absorption. Animal toxicity studies have shown that it is safe, and the No Observed Effect Level was 2 ml/kg body weight in tested animals. It was not mutagenic and shared similar cytotoxicity profile with other imidazole antifungal products studied. Penetration studies using synthetic membranes revealed that eberconazole intrasets showed less variation as compared to clotrimazole and terbinafine intrasets. Overall amount of eberconazole released was more compared to comparators. In vitro and preclinical studies have demonstrated better therapeutic efficacy with eberconazole than clotrimazole and ketoconazole.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded479    
    Comments [Add]    

Recommend this journal